

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Qianhai Health Holdings Limited**

**前海健康控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

(Stock Code: 911)

## **POSITIVE PROFIT ALERT**

This announcement is made by board (the “**Board**”) of directors (the “**Directors**”) of the Qianhai Health Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary review of the Group’s unaudited management accounts for the year ended 31 December 2024 (the “**Year**”) (the “**Management Accounts**”), and information currently available to the Board, the Group is expected to record a net profit attributable to the Shareholders of approximately HK\$1.3 million (the “**Expected Profit**”), which represent a turnaround from the loss of approximately HK\$52.7 million recorded for the year ended 31 December 2023 (the “**Prior Year**”).

The turnaround from loss to profit for the Year was primarily attributable to the combined effect of (i) a transition from gross loss of the Prior Year to gross profit of the Year of approximately HK\$29.7 million, as the Group’s strategic shift towards a higher-margin product mix; (ii) an one-off gain on disposal of subsidiaries amounting to approximately HK\$51.9 million; and (iii) off set by the provision for onerous contracts of approximately HK\$54.0 million due to the decrease in market prices of electronic component products (especially semiconductors) in the last quarter of 2024.

The Company is still in the process of finalising its annual results for the Year. The information contained in this announcement is only a preliminary assessment by the Board based on the Management Accounts and the latest information currently available, which have not been reviewed by the audit committee of the Company and may be subject to adjustments. In particular, the exact amount of provision for onerous contracts and provision for inventories to be recognised for the Year may be affected by the subsequent selling price and/or market price trend of the related electronic components products. Actual financial results for the Year may be different from what is disclosed in this announcement. Further details of the Group's financial results and performance will be disclosed in the Company's annual results announcement which is expected to be published in March 2025 in accordance with the requirements of the Listing Rules.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Qianhai Health Holdings Limited**  
**Huang Zhiqun**  
*Chairman*

Hong Kong, 6 March 2025

*As at the date of this announcement, the non-executive Directors are Mr. Huang Zhiqun, Mr. Chen Kaiben and Mr. Chen Qi; the executive Directors are Mr. Tang Yu Yuan and Mr. Yuen Chee Lap Carl; and the independent non-executive Directors are Mr. Li Wei, Mr. Leung Chun Tung and Ms. Wu Hung Yu.*